Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$141 Mln
P/E Ratio
--
P/B Ratio
2.58
Industry P/E
--
Debt to Equity
-0.61
ROE
-7.06 %
ROCE
304.97 %
Div. Yield
0 %
Book Value
--
EPS
-1.5
CFO
$-975.48 Mln
EBITDA
$-1,047.46 Mln
Net Profit
$-1,201.61 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Adc Therapeutics SA (ADCT)
| -35.17 | 5.75 | -12.83 | -70.00 | -43.01 | -- | -- |
|
BSE Sensex
| 3.71 | 7.97 | 6.53 | 11.68 | 15.31 | 20.93 | 11.68 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
|
|---|---|---|---|
|
Adc Therapeutics SA (ADCT)
| -56.77 | -80.99 | -36.89 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 1.62 | 168.69 | -- | -46.3 | |
| 0.08 | 2.89 | -- | 531.41 | |
| 37.14 | 3,076.27 | -- | -20.47 |
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received... accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland. Address: BiopOle, Epalinges, Switzerland, 1066 Read more
CEO & Director
Dr. Ameet Mallik M.B.A., M.S.
CEO & Director
Dr. Ameet Mallik M.B.A., M.S.
Headquarters
Epalinges
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Adc Therapeutics SA (ADCT) stood at $ 322 Mln as on 31-Dec-24
The share price of Adc Therapeutics SA (ADCT) is $1.29 (NYSE) as of 13-May-2025 14:35 EDT. Adc Therapeutics SA (ADCT) has given a return of -43.01% in the last 3 years.
Adc Therapeutics SA (ADCT) has a market capitalisation of $ 141 Mln as on 08-May-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Adc Therapeutics SA (ADCT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Adc Therapeutics SA (ADCT) and enter the required number of quantities and click on buy to purchase the shares of Adc Therapeutics SA (ADCT).
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland. Address: BiopOle, Epalinges, Switzerland, 1066
The CEO & director of Dr. Ameet Mallik M.B.A., M.S.. is Adc Therapeutics SA (ADCT), and CFO & Sr. VP is Dr. Ameet Mallik M.B.A., M.S..
There is no promoter pledging in Adc Therapeutics SA (ADCT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
408
|
|
|
31
|
|
|
1
|
|
|
408
|
| Adc Therapeutics SA (ADCT) | Ratios |
|---|---|
|
Return on equity(%)
|
89.97
|
|
Operating margin(%)
|
-154.43
|
|
Net Margin(%)
|
-227.84
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Adc Therapeutics SA (ADCT) was $0 Mln.
$0.02
(
